Efficacy of canakinumab in mild or severe COVID‐19 pneumonia

Immunity, Inflammation and Disease

Marta Di Nicola¹  Michele Marchioni¹  Di Penta Myriam²  Celletti Eleonora²  Sabatini Emanuela²  Francesco Cipollone²  Antonio Auricchio³  Jacopo Vecchiet³  Falasca Katia³  Claudio Ucciferri⁴ 

[1] Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy;Department of Medicine and Aging Sciences, Internal Medicine, “G. D'Annunzio” University, Chieti, Italy;Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University “G. d'Annunzio” Chieti‐Pescara, Chieti, Italy;Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University “G. d'Annunzio” Chieti‐Pescara, Chieti, Italy;Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy;

关键词: IL1‐β;    monoclonal antibody;    safety;    SARS COV2;    therapy;   

DOI  :  10.1002/iid3.400

来源: Wiley

【 授权许可】

CC BY